BACKGROUND Drug-eluting stents have improved the efficacy of percutaneous coronary intervention and made it the preferred therapy in the treatment of ischemic heart diseases including acute coronary syndromes. The objective of the study was to compare the clinical efficacy and safety of sirolimus-eluting stent with that of zotarolimus-eluting stent following percutaneous coronary intervention f...

Stent fracture is a complication following implantation of drug eluting stents and is recognized as one of the risk factors for in-stent restenosis. We present the first case of successfully managing a stent fracture and subsequent migration of the fractured stent into the ascending aorta that occurred during repeat revascularization for in-stent restenosis of an ostium of saphenous vein graft ...

BACKGROUND Binary angiographic and clinical restenosis rates can vary widely between clinical studies, even for the same stent, influenced heavily by case-mix covariates that differ among observational and randomized trials intended to assess a given stent system. We hypothesized that mean in-stent late loss might be a more stable estimator of restenosis propensity across such studies. METHOD...

Background—Guidelines recommend that noncardiac surgery be delayed until 30 to 45 days after bare-metal stent implantation and 1 year after drug-eluting stent implantation. Methods and Results—We used linked registry data and population-based administrative health care databases to conduct a cohort study of 8116 patients (Ն40 years of age) who underwent major elective noncardiac surgery in Onta...

Evaluation of: Sanchez, P, Gimeno F, Ancillo P et al.: Role of the paclitaxel-eluting stent and tirofiban in patients with ST elevation myocardial infarction undergoing postfibrinolysis angioplasty (GRACIA 3 Trial). Circ. Cardiovasc. Interv. 3, 297–307 (2010). In ST elevation myocardial infarction patients presenting to nonpercutaneous coronary intervention (PCI)-capable hospitals, a pharmacoin...

BACKGROUND Guidelines recommend that noncardiac surgery be delayed until 30 to 45 days after bare-metal stent implantation and 1 year after drug-eluting stent implantation. METHODS AND RESULTS We used linked registry data and population-based administrative health care databases to conduct a cohort study of 8116 patients (≥40 years of age) who underwent major elective noncardiac surgery in On...

BACKGROUND Previous randomized trials have showed the superiority of Paclitaxel-eluting stent over bare metal stent in angiographic and clinical outcomes. Coroflex Please stent is a newly developed drug eluting stent using the Coroflex stent platform combined with the drug paclitaxel contained in a polymer coating. PECOPS I trial, one-arm observational study, showed that the clinical and angiog...

Dear Editor, Currently, coronary stent implantation is employed in approximately 90% of percutaneous coronary intervention (PCI) cases. Despite the use of drug-eluting stents (DES), coronary in-stent restenosis (ISR) remains an Achilles’ heel of PCI and can occur in about 10% of patients in the real-world population.1,2 We explored the effi cacy of a novel approach using drug-eluting balloon (D...

BACKGROUND The impact of adherence to the recommended duration of dual antiplatelet therapy after first generation drug-eluting stent implantation is difficult to assess in real-world settings and limited data are available. METHODS We followed 4,154 patients treated with coronary drug-eluting stents in Western Denmark for 1 year and obtained data on redeemed clopidogrel prescriptions and maj...

OBJECTIVES The aim of this study was to explore the safety and efficacy of a dedicated drug-eluting stent for the treatment of coronary lesions with very small reference vessel diameter (RVD). BACKGROUND Smaller RVD is associated with increased risk for restenosis and target lesion failure (TLF) after stent implantation. METHODS This was a prospective, single-arm, multicenter trial of the R...